19 Hrs
Source:
الاتحاد
New vaccine lowers skin cancer return
A study has shown that an experimental vaccine based on messenger RNA (mRNA) technology, called Intesimiran and developed by Moderna, combined with Merck's immunotherapy drug Keytruda, significantly reduces the risk of skin cancer recurrence after five years compared to treatment with the drug alone. The results indicated that 68.8% of patients who received the combined therapy showed no signs of disease recurrence, compared to 49.1% of those who received only Keytruda, with the survival rate increasing to 92.2%. The study confirmed that the combined therapy reduces the risk of tumor recurrence by 49% and leads to a noticeable improvement in patient outcomes.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)